Company Overview

Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring, developing, and commercializing pharmaceutical and biotechnology products through a diversified portfolio structure. The company operates primarily in the biotechnology and specialty pharmaceutical industries, with activities spanning drug development, product commercialization, and strategic healthcare investments. Fortress Biotech generates value through majority-owned and partner companies that advance therapies targeting oncology, rare diseases, dermatology, infectious diseases, and gene therapy. Revenue is derived from product sales, licensing arrangements, royalties, collaborative agreements, milestone payments, and equity interests in subsidiaries and partner entities.

The company was founded in 2006 and is headquartered in Bay Harbor Islands, Florida. Fortress Biotech evolved from a healthcare-focused acquisition and development platform into a holding company model designed to incubate and finance multiple biotechnology programs simultaneously. Its structure allows subsidiary companies to operate with relative independence while leveraging centralized capital access, management expertise, and regulatory support. The company’s strategic positioning is tied to its diversified pipeline model, which reduces dependence on a single product candidate while providing exposure to multiple therapeutic areas and commercialization pathways.

Business Operations

Fortress Biotech conducts operations through a network of subsidiary and partner companies, including Journey Medical Corporation, Mustang Bio, Inc., Avenue Therapeutics, Inc., and other development-stage entities. The company’s operating structure includes both commercial-stage and clinical-stage businesses. Journey Medical Corporation focuses on dermatology products and commercial distribution, while Mustang Bio, Inc. concentrates on cell and gene therapies, particularly CAR-T and hematopoietic stem cell technologies. Fortress also maintains interests in oncology therapeutics, anti-infective products, and rare disease assets through various affiliated companies.

Operations span both domestic and international activities, with clinical trials, licensing agreements, manufacturing relationships, and research collaborations extending beyond the United States. Fortress Biotech controls or holds rights to a broad portfolio of intellectual property, development licenses, and commercialization assets obtained through acquisitions and partnerships with academic institutions and biotechnology firms. The company has collaborated with organizations such as City of Hope, Fred Hutchinson Cancer Center, and other research institutions to advance proprietary therapeutic technologies. Revenue generation varies across subsidiaries, with commercial dermatology sales representing a more established revenue stream relative to earlier-stage development programs.

Strategic Position & Investments

Fortress Biotech’s strategy centers on building a diversified pipeline of therapeutics through acquisitions, licensing transactions, and subsidiary formation. The company has invested in multiple therapeutic platforms designed to create long-term optionality across different stages of clinical development. Key strategic initiatives have included expanding commercial dermatology operations through Journey Medical Corporation, advancing cell therapy programs through Mustang Bio, Inc., and supporting development-stage oncology and neurology assets across affiliated companies.

The company has completed numerous licensing and acquisition transactions involving academic institutions and biotechnology developers. Fortress has also used public listings and equity financings for subsidiaries as a mechanism to raise capital while maintaining strategic ownership stakes. Emerging areas of investment include gene therapy, CAR-T therapies, and precision oncology. Several subsidiaries remain dependent on regulatory approvals, clinical milestones, and capital market access to advance pipeline candidates. Public disclosures indicate ongoing efforts to optimize portfolio allocation and support programs with the highest commercial and regulatory potential.

Geographic Footprint

Fortress Biotech is headquartered in Florida, United States, with operations and subsidiary activities concentrated primarily in the United States. Its commercial presence is strongest in the U.S. specialty pharmaceutical and biotechnology markets, particularly through dermatology product commercialization and clinical development programs. The company’s subsidiaries engage with contract manufacturers, clinical research organizations, and academic collaborators across multiple regions.

International exposure is primarily achieved through licensing relationships, clinical trial activity, and research partnerships rather than large-scale foreign commercial operations. Fortress Biotech’s therapeutic programs have involved collaborations with institutions and service providers in North America and parts of Europe, reflecting the global nature of biotechnology research and regulatory development. Data regarding substantial direct operating infrastructure outside the United States is limited in publicly available filings.

Leadership & Governance

Fortress Biotech was founded by Lindsay A. Rosenwald, M.D., who has played a central role in the company’s strategic development and investment philosophy. The company’s governance approach emphasizes decentralized subsidiary management combined with centralized financial and operational oversight. Leadership has consistently articulated a strategy focused on identifying undervalued or promising therapeutic assets, supporting them through development, and monetizing opportunities through commercialization, partnerships, or public market transactions.

Key executives include:

• Lindsay A. Rosenwald, M.D. – Chairman, President and Chief Executive Officer
• Michael S. Weiss – Executive Vice Chairman, Strategic Development
• Jaclyn Jaffe – Chief Financial Officer
• David Jin, Ph.D. – Chief Executive Officer of Mustang Bio, Inc.
• Claude Maraoui – Chief Executive Officer of Journey Medical Corporation

The company’s leadership team includes executives with backgrounds in biotechnology finance, pharmaceutical commercialization, clinical development, and healthcare investment management. Governance and operational disclosures are primarily detailed in SEC filings, including annual reports on Form 10-K, quarterly reports on Form 10-Q, and proxy statements.